EP0731177A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method of characterising genomic DNA
Assignee: AstraZeneca UK Ltd
•
Filing: 1992-08-26
•
Granted: —
•
Expires: 2012-08-26
Abstract
Abstract A novel method for the detection of diagnostic base sequences in one or more nucleic acids contained in a sample.
Inventors
- 👤 Alec John University Of Leicester Jeffreys
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-01 10:46
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/68; C12Q1/6844; C12Q1/6858; C12Q1/686; C12Q2600/00; C12Q2600/156
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
248 words
A method for detecting the presence or absence of at least one diagnostic base sequence in one or more nucleic acids contained in a sample, which method comprises contacting the sample with a diagnostic primer for each diagnostic base sequence, the nucleotide sequence of each diagnostic primer being such that it is substantially complementary to the corresponding diagnostic base sequence, under hybridising conditions and in the presence of appropriate nucleoside triphosphates and an agent for polymerisation thereof, such that an extension product of a diagnostic primer is synthesised when the corresponding diagnostic base sequence is present in the sample, no extension product being synthesised when the corresponding diagnostic base sequence is not present in the sample and any extension product of a diagnostic primer acts as template for extension of a further primer which hybridises to a locus at a distance from the relevant diagnostic base sequence, and wherein at least one of the diagnostic primer(s) further comprises a tail sequence which does not hybridise to a diagnostic base sequence or a region adjacent thereto, and contacting the above mixture with a tail specific primer which hybridises to the complement of the tail sequence in an extension product of the further primer and is extended in the presence of appropriate nucleoside triphosphates and an agent for polymerisation thereof to amplify the further primer amplification products whereby the presence or absence of the diagnostic base sequence(s) is detected from the presence or absence of tail specific primer extension product.
Claim 2
Dependent Claim
32 words
A method as claimed in claim 1 wherein a single, common tail specific primer is used for all the diagnostic primers comprising tail sequences for use with the common tail specific primer.
Claim 3
Dependent Claim
36 words
A method as claimed in claim 1 or claim 2 wherein a single common tail specific primer is used for all primers and these all comprise tail sequences for use with the common tail specific primer.
Claim 4
Independent Claim
23 words
A method as claimed in any one of claims 1-3 wherein one or more of the diagnostic primers is an allele specific primer.
Claim 5
Independent Claim
31 words
A method as claimed in any one of the previous claims wherein two or more competitive oligonucleotide primers are used to detect variant nucleotide(s) in at least one diagnostic base sequence.
Claim 6
Independent Claim
89 words
A method as claimed in any one of claims 1-4 wherein a terminal nucleotide of at least one diagnostic primer is either complementary to a suspected variant nucleotide or to the corresponding normal nucleotide, such that an extension product of a diagnostic primer is synthesised when the terminal nucleotide of the diagnostic primer is complementary to the corresponding nucleotide in the diagnostic base sequence, no extension product being synthesised when the terminal nucleotide of the diagnostic primer is not complementary to the corresponding nucleotide in the diagnostic base sequence.
Claim 7
Independent Claim
25 words
A method as claimed in any one of claims 1-4 or 6 wherein extension products of at least two diagnostic primers comprise a complementary overlap.
Claim 8
Dependent Claim
18 words
A method as claimed in claim 7 and wherein at least two diagnostic primers comprise a complementary overlap.
Claim 9
Independent Claim
27 words
A method as claimed in any one of the previous claims wherein the ratio of tail specific and/or further primer(s) to diagnostic primer(s) is at least 1:1.
Claim 10
Dependent Claim
14 words
A method as claimed in claim 9 wherein the ratio is at least 50:1.
Claim 11
Dependent Claim
198 words
A kit for detecting the presence or absence of at least one variant nucleotide in one or more nucleic acids contained in a sample, which kit comprises:- a diagnostic primer for each diagnostic portion of a target base sequence, the nucleotide sequence of each diagnostic primer being such that it is substantially complementary to the said diagnostic portion, a terminal nucleotide of the diagnostic primer being either complementary to the suspected variant nucleotide or to the corresponding normal nucleotide, such that in use an extension product of the diagnostic primer is synthesised when the said terminal nucleotide of the diagnostic primer is complementary to the corresponding nucleotide in the target base sequence, no extension product being synthesised when the said terminal nucleotide of the diagnostic primer is not complementary to the corresponding nucleotide in the target base sequence; at least one diagnostic primer further comprising a tail sequence for hybridisation to a tail specific primer which hybridises to the complement of the tail sequence in the extension product of the common primer and which tail sequence does not hybridise to the target base sequence or a region adjacent thereto, together with appropriate buffer, packaging and instructions for use.
Claim 12
Dependent Claim
62 words
A kit as claimed in claim 11 which further comprises at least one of the following items: (i) each of four different nucleoside triphosphates (ii) an agent for polymerisation of the nucleoside triphosphates in (i) (iii) tail specific primer(s) (iv) a second primer which hybridises to a region at a distance from the diagnostic region(s) to which the diagnostic primer(s) selectively hybridise.
Claim 13
Dependent Claim
29 words
A kit as claimed in claim 11 or claim 12 which comprises a set of at least two diagnostic primers for each diagnostic portion of a target base sequence.
Claim 14
Dependent Claim
43 words
A kit as claimed in claim 13 wherein a terminal nucleotide of one diagnostic primer is complementary to a suspected variant nucleotide associated with a known genetic disorder and a terminal nucleotide of another diagnostic primer is complementary to the corresponding normal nucleotide.
Claim 15
Independent Claim
19 words
A method as claimed in any one of claims 1-10 and performed as a homogenous polymerase chain reaction assay.
Claim 16
Independent Claim
24 words
A method as claimed in any one of claims 1-10 or 15 wherein intercalating dye(s) are used to detect tail specific primer extension products.
Claim 17
Independent Claim
42 words
A method as claimed in any one of claims 1-10, 15 or 16 wherein the diagnostic primer and tail specific primer sequences are selected such that an increase in temperature is used to favour tail specific primer priming over diagnostic primer priming.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.